Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome

References

• Zhong NS, Zheng BJ, Li YM et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in Feburary, 2003. Lancet 363, 1353–1358 (2003).
   Google Scholar
• Centers for Disease Control and Prevention. Update: outbreak of severe acute respiratory syndrome – worldwide. Morbid. Mortal. Wkly Rep. 52, 241–248 (2003).
   PubMedGoogle Scholar
• Lau JTF, Tsui H, Lau M, Yang X. SARS transmission, risk factors, and prevention in Hong Kong. Emerg. Infect. Dis. 10(4), 587–592 (2004).
   PubMed Web of Science ®Google Scholar
• Guan Y, Zheng BJ, He YQ et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276–278 (2003).
   PubMed Web of Science ®Google Scholar
• Peiris JS, Lai ST, Poon LL et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325 (2003).
   PubMed Web of Science ®Google Scholar
• The Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 303, 1666–1669 (2004).
   PubMed Web of Science ®Google Scholar
• Zheng B, Guan Y, Wong K et al. SARS-related virus predating SARS outbreak, Hong Kong. Emerg. Infect. Dis. 10, 176–178 (2004).
   PubMed Web of Science ®Google Scholar
• Peiris JS, Chu CM, Cheng VC et al. Clinical progression and viral load in an outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 (2003).
   PubMed Web of Science ®Google Scholar
• Christian MD, Loutfy M, McDonald LC et al. Possible SARS coronavirus transmission during cardiopulmonary resuscitation. Emerg. Infect. Dis. 10(2), 287–293 (2004).
   PubMed Web of Science ®Google Scholar
• Yu IGT, Li Y, Wong TW et al. Evidence of airborne transmission of the severe acute respiratory virus. N. Engl. J. Med. 350, 1731–1739 (2004).
   PubMed Web of Science ®Google Scholar
• Riley S, Fraser C, Donnelly C et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 300, 1961–1966 (2003).
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H. The prevaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol. Infect. 125, 635–650 (2000).
   PubMed Web of Science ®Google Scholar
• Svoboda T, Henry B, Shulman L. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N. Engl. J. Med. 350(23), 2352–2361 (2004).
   PubMed Web of Science ®Google Scholar
• Lau J, Fung K, Wong T et al. SARS transmission among hospital workers in Hong Kong. Emerg. Infect. Dis. 10, 280–286 (2004).
   PubMed Web of Science ®Google Scholar
• Booth CM, Matukas LM, Tomlinson GA et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. J. Am. Med. Assoc. 289(21), 2801–2809 (2003).
   PubMed Web of Science ®Google Scholar
• Avendano M, Derkach P, Swan S. Clinical course and management of SARS in healthcare workers in Toronto: a case series. Can. Med. Assoc. J. 168(13), 1649–1660, (2003).
   PubMed Web of Science ®Google Scholar
• Lee N, Hui D, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348(20), 1986–1994 (2003).
   PubMed Web of Science ®Google Scholar
• Chan TY, Miu KY, Tsui CK, Yee KS, Chan MH. A comparative study of clinical features and outcomes in young and older adults with severe acute respiratory syndrome. J. Am. Geriat. Soc. 52, 1321–1325 (2004).
   PubMedGoogle Scholar
• Karlberg J, Chong DSY, Lai WYY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am. J. Epidemiol. 159, 229–231 (2004).
   PubMed Web of Science ®Google Scholar
• Chan JW, Ng CK, Chan YH et al. Short-term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome. Thorax 58, 686–689 (2003).
   PubMed Web of Science ®Google Scholar
• Lam CM, Wong SF, Leung TN et al. A case-controlled study comparing clinical course and outcomes of pregnant and nonpregnant women with severe acute respiratory syndrome. Br. J. Obstet. Gynaecol. 111, 771–774 (2004).
   Google Scholar
• Chan KH, Poon LLM, Cheng VCC et al. Detection of SARS coronavirus (SCoV) by RT-PCR, culture, and serology in patients with acute respiratory syndrome (SARS). Emerg. Infect. Dis. 10, 294–299 (2003).
   Google Scholar
• Ng EKO, Hui DS, Chan KCA et al. Quantitative analysis and prognostic implication of sars coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin. Chem. 49(12), 1976–1980 (2003).
   PubMed Web of Science ®Google Scholar
• Poon LLM, Wong BW, Chan KH et al. A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors. J. Clin. Virol. 30, 214–217 (2004).
   PubMedGoogle Scholar
• Mandell LA, Bartlett JG, Dowell S, File TM, Musher D, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37, 1405–1433 (2003).
   PubMed Web of Science ®Google Scholar
• Lew TWK, Kewk TK, Tai D et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. J. Am. Med. Assoc. 290, 374–380 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang F, Xu M et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangdong, PR China. J. Med. Microbiol. 52(8), 715–720 (2003).
   PubMed Web of Science ®Google Scholar
• Pearlman BL. Hepatitis C treatment update. Am. J. Med. 117(5), 344–352 (2004).
   PubMed Web of Science ®Google Scholar
• Chen F, Chan KH, Jiang Y et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 31, 69–75 (2004).
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VCC, Hung IFN et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252–256 (2004).
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361, 2045–2046 (2003).
   PubMed Web of Science ®Google Scholar
• Tan ELC, Ooi EE, Lin CY et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10(4), 581–586 (2004).
   PubMed Web of Science ®Google Scholar
• Mazzulli T, Farcas GA, Poutanen SM et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg. Infect. Dis. 10(1), 20–24 (2004).
   PubMed Web of Science ®Google Scholar
• Samuel CE. Antiviral action of IFNs. Clin. Microbiol. Rev. 14, 778–809 (2001).
   PubMed Web of Science ®Google Scholar
• Poynard T. Treatment of hepatitis C virus: the first decade. Semin. Liver Dis. 24(S2), 19–24 (2004).
   PubMedGoogle Scholar
• Biron CA. Interferons-α and -β as immune regulators – a new look. Immunity 14, 661–664 (2001).
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Blatt L, Siminovitch K et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome. J. Am. Med. Assoc. 290(24), 3222–3228 (2003).
   PubMed Web of Science ®Google Scholar
• Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 25, 283–291 (1996).
   PubMed Web of Science ®Google Scholar
• Bruno S, Camma C, Di Marco V et al. Peginterferon-α2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J. Hepatol. 41(3), 474–481 (2004).
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 362, 293–294 (2003).
   PubMed Web of Science ®Google Scholar
• Hensley LE, Fritz EA, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon β1a and SARS coronavirus replication. Emerg. Infect. Dis. 10(2), 317–319 (2004).
   PubMed Web of Science ®Google Scholar
• Tanabe Y, Sakamoto N, Enomoto N et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α. J. Infect. Dis. 189(7), 1129–1139 (2004).
   PubMedGoogle Scholar
• Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Comm. 326, 905–908 (2005).
   Google Scholar
• Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 36(12), 1585–1592 (2003).
   PubMed Web of Science ®Google Scholar
• Chen XP, Cao Y. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin. Infect. Dis. 38, 1030–1032 (2004).
   PubMedGoogle Scholar
• Hurst M, Faulds D. Lopinavir. Drugs 60, 1371–1379 (2000).
   Google Scholar
• Chan KS, Lai ST, Chu CM et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med. J. 9, 399–406 (2003).
   PubMedGoogle Scholar
• De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol. 30(2), 115–133 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Yang R, Yoshinaka Y et al. HIV protease inhibitor neflinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 318(3), 719–725 (2004).
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Murashima N et al. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79, 1494–1500 (1997).
   Google Scholar
• van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Glycyrrhizin as a potential treatment for chronic hepatitis C. Ail. Pharmacol. Ther. 12, 199–205 (1998).
   PubMed Web of Science ®Google Scholar
• Wu CJ, Jan JT, Chen CM et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother. 48(7), 2693–2696 (2004).
   PubMed Web of Science ®Google Scholar
• Chen L, Lui P, Gao H et al. Inhalation of nitric oxide in the treatment of SARS: a rescue study in Beijing. Clin. Infect. Dis. 39(10), 1531–1535 (2004).
   PubMed Web of Science ®Google Scholar
• Movahed P, Hogestatt ED, Petersson J. Effect of hypoxia on vasodilator responses to S-nitroso-N-acetylpenicillamine and levcromakalim in guinea-pig basilar artery. Naunyn. Schmiedebergs Arch. Pharmacol. 367(5), 532–557 (2003).
   PubMedGoogle Scholar
• Keyaerts E, Vijgen L, Chen L, Maes P, Hedenstierna G, Van Ranst M. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int. J. Infect. Dis. 8(4), 223–226 (2004).
   PubMed Web of Science ®Google Scholar
• Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Comm. 323, 264–268 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 27(1), 25–61 (2004).
   PubMed Web of Science ®Google Scholar
• Yuan K, Yi L, Chen J. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem. Biophys. Res. Commun. 319(3), 746–752 (2004).
   PubMed Web of Science ®Google Scholar
• Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 24(2), 198–211 (2004).
   PubMedGoogle Scholar
• Wang Z, Ren L, Zhao X et al. Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J. Virol. 78(14), 7523–7527 (2004).
   PubMed Web of Science ®Google Scholar
• Shi Y, Luo H, Jia J et al. Antisense downregulation of SARS-CoV gene expression in Vero E6 cells. J. Genet. Med. 7, 97–107 (2005).
   Google Scholar
• Novina CD, Murrary MF, Dykxhoorn DM et al. siRNA-directed inhibition of HIV-1 infection. Nature Med. 8, 681–686 (2002).
   PubMed Web of Science ®Google Scholar
• Wong CK, Lam CW, Wu AK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136(1), 95–103 (2004).
   PubMed Web of Science ®Google Scholar
• Charles M. Severe acute respiratory syndrome (SARS) and coronavirus testing – USA, 2003. The CDC SARS Investigative Team. Morb. Mortal. Wkly Rep. 52, 297–302 (2003).
   PubMedGoogle Scholar
• Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N. Engl. J. Med. 337, 1285–1292 (1997).
   PubMed Web of Science ®Google Scholar
• Montaner JS, Lawson LM, Levitt N et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 113, 14–20 (1990).
   PubMed Web of Science ®Google Scholar
• Smego RA, Ahmed N. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 7, 208–213 (2003).
   PubMed Web of Science ®Google Scholar
• Delclaux C, Zahar JR, Amraoui G et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in nonhuman immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin. Infect. Dis. 29(3), 670–672 (1999).
   PubMed Web of Science ®Google Scholar
• Wong KT, Antonio GE, Hui DSC et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 228, 401–406 (2003).
   PubMed Web of Science ®Google Scholar
• Tse GMK, To KF, Chan PKS et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J. Clin. Pathol. 57, 260–265 (2004).
   PubMed Web of Science ®Google Scholar
• Bernard GR. Corticosteroids: the ‘terminator’ of all untreatable serious pulmonary illness. Am. J. Respir. Crit. Care Med. 168(12), 1409–1410 (2003).
   PubMedGoogle Scholar
• Ho JC, Ooi GC, Mok TY et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am. J. Respir. Crit. Care Med. 168, 1449–1456 (2003).
   PubMed Web of Science ®Google Scholar
• Gomersall CD, Joynt GM, Lam P et al. Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med. 30, 381–387 (2004).
   PubMed Web of Science ®Google Scholar
• Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. J. Gastroenterol. Hepatol. 11(2), 143–147 (1996).
   PubMed Web of Science ®Google Scholar
• Buckingham SC, Jafri HS, Bush AJ et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J. Infect. Dis. 185, 1222–1228 (2002).
   PubMedGoogle Scholar
• Lee N, Chan KCA, Hui DS et al. Effects of early treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J. Clin. Virol. 31, 304–309 (2004).
   PubMed Web of Science ®Google Scholar
• Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin. Radiol. 59, 602–608 (2004).
   PubMed Web of Science ®Google Scholar
• Epstein NN, Tuffanelli DL, Epstein JH. Avascular bone necrosis. A complication of long-term corticosteroid therapy. Arch. Dermatol. 92(2), 178–180 (1965).
   Google Scholar
• Wong VW, Dai D, Wu AK et al. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med. J. 9, 199–210 (2003).
   PubMedGoogle Scholar
• Soo YO, Cheng Y, Wong R et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin. Microbiol. Infect. 10(7), 676–678 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong R, Soo Y et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44–46 (2005).
   PubMed Web of Science ®Google Scholar
• Navas-Martin S, Weiss SR. Coronavirus replication and pathogenesis: implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development. J. Neurovirol. 10, 75–85 (2004).
   PubMedGoogle Scholar
• Denison MR. Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update. Pedeatr. Infect. Dis. J. 23(11), S207–S214 (2004).
   Google Scholar
• Lau YL. SARS: future research and vaccine. Pedeatr. Resp. Rev. 5, 300–303 (2004).
   PubMedGoogle Scholar
• Bukreyev A, Lamirande EW, Buchholz UJ. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 22–27 (2004).
   Google Scholar
• Marshall E, Enserink M. Caution urged on SARS vaccines. Science 303, 944–946 (2004).
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wu A, Joynt GM et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 59(5), 414–420 (2004).
   PubMed Web of Science ®Google Scholar